search
Back to results

Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice (NorTick_EM)

Primary Purpose

Erythema Migrans, Erythema Chronicum Migrans, Borreliosis

Status
Completed
Phase
Phase 4
Locations
Norway
Study Type
Interventional
Intervention
Doxycycline
Phenoxymethylpenicillin
Amoxicillin
Sponsored by
Morten Lindbaek
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Erythema Migrans focused on measuring Antibiotics, General Practice, Erythema migrans, Borrelia, Ticks

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical diagnosis of Erythema migrans
  • Over the age of 18
  • Signing an concent form after information in writing

Exclusion Criteria:

  • Allergic to any of the three drugs in the study
  • Under the age of 18
  • Pregnancy
  • Dementia or known drug abuse
  • Antibiotic treatment last 14 days
  • Concommitant Chemotherapy or immunomodulating therapy
  • Concommitant use of medicine with potential interaction (defined in protocol)

Sites / Locations

  • Antibiotic Centre for Primary Care, University of Oslo

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

Doxycycline

Penicillin

Amoxicillin

Arm Description

Doxycycline, 100 mg, tablets, b.i.d., 14 days

Phenoxymethylpenicillin tablets 650 mg. 2 tablets t.i.d. 14 days

Amoxicillin 500 mg capsula, t.i.d., 14 days

Outcomes

Primary Outcome Measures

Duration of Erythema migrans (EM)
On day 1 duration until first the consulation is registered. Day 1-14 the EM is registered in a patient diary. On day 14 the doctor is asked whether the EM has disseapeared. If not the patient is followed by phone from the researchers. On day 90 they are additionally asked for how long it lasted.

Secondary Outcome Measures

Subjective Health Complaints (SHC)
By questionnaire on day 1, day 90 and day 360 the patients are asked about their SHC which is a standardized set of parametres. The 3 treatment groups are compaired to each other and to 1200 healthy blood donors receiving the same questionnaire. There are 29 standardized and 3 Lyme disease related subjects to be measured.
Borrelia antibodies
Normally antibody production is not measured for EM as it is a clinical diagnosis, and less than 50 percent of EM-patients are expected to develop antibodies in the first period. However antibodies are here measured on day 1, day 14 and day 90 to see whether there are differences between the groups. Also the results will be compared to the blood donors.
Side symptoms
The EM in it self is often asymptomatic, and fever, headache and nerval palsy can be a sign of disseminated disease or co-infection. On the quiestionnaire to the pasient and doctor on day 1, in the patient diary day 1-14 and on the questionnaire to the doctor on day 14 these side symptoms are registered. In a potential case, where it turns out that the patient suffers from disseminated disease this will be regostered as treatment failure in the study and the patient treated and/or referred as normal.
Side effects
The antibiotic tretments are expected to be non-inferior to each other. Potensial side effects as nausea, diarrhea etc. are registered in the patients diary day 1-14 and in the doctors quiestionnaire on day 14.
Subgrouping and TBE
For volunteers there is an additional PCR-analysis on punch biopsy from the EM for subgroupring of the Borrelia bacteria. TBE-antibodies are measured on day 14.

Full Information

First Posted
June 6, 2011
Last Updated
December 11, 2014
Sponsor
Morten Lindbaek
Collaborators
Norwegian Institute of Public Health, Sorlandet Hospital HF, Norwegian University of Life Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT01368341
Brief Title
Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice
Acronym
NorTick_EM
Official Title
Tick Borne Diseases in Norwegian General Practice. A Randomized, Controlled Trial for Treatment of Erythema Migrans in Norwegian General Practice. A Comparison of Phenoxymethylpenicillin, Amoxicillin and Doxycycline.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2014
Overall Recruitment Status
Completed
Study Start Date
June 2011 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Morten Lindbaek
Collaborators
Norwegian Institute of Public Health, Sorlandet Hospital HF, Norwegian University of Life Sciences

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Tick borne diseases are increasing in Norway. Lyme borreliosis is the most common infection. Erythema migrans is mainly diagnosed and treated in general practice. There is disagreement about what antibiotic treatment that should be given. An RCT with the three most common antibiotics used, will support data for revision of national guidelines.
Detailed Description
Comparison of phenoxymethylpenicillin, doxycycline and amoxicillin for Erythema migrans in Norwegian general practice. Every patient receives 14 days of antibiotic treatment. There are blood samples for measurement of Borrelia antibody level at day 1, 14 and 90 and questionnaires on subjective health complaints (SHC) at day 1, 90 and 360. Side symptoms and side effects are registered. For volunteers there is an additional PCR-analysis on punch biopsy from the EM for subgrouping of the Borrelia bacteria. TBE-antibodies are measured on day 14. Antibody levels and SHC-scores are compared to healthy blood donors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Erythema Migrans, Erythema Chronicum Migrans, Borreliosis, Lyme Disease, Early Lyme Disease
Keywords
Antibiotics, General Practice, Erythema migrans, Borrelia, Ticks

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
225 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Doxycycline
Arm Type
Active Comparator
Arm Description
Doxycycline, 100 mg, tablets, b.i.d., 14 days
Arm Title
Penicillin
Arm Type
Active Comparator
Arm Description
Phenoxymethylpenicillin tablets 650 mg. 2 tablets t.i.d. 14 days
Arm Title
Amoxicillin
Arm Type
Active Comparator
Arm Description
Amoxicillin 500 mg capsula, t.i.d., 14 days
Intervention Type
Drug
Intervention Name(s)
Doxycycline
Other Intervention Name(s)
Doksycycline 100 mg HEXAL, no. 30
Intervention Description
1 tablet, 100 mg, b.i.d. 14 days
Intervention Type
Drug
Intervention Name(s)
Phenoxymethylpenicillin
Other Intervention Name(s)
Weifapenin 650 mg, WEIFA, no. 100
Intervention Description
Tablet 650 mg, 2 tablets, t.i.d., 14 days
Intervention Type
Drug
Intervention Name(s)
Amoxicillin
Other Intervention Name(s)
Amoxicillin 500 mg MYLAN, no. 30 + 20.
Intervention Description
Capsula, 500 mg, t.i.d., 14 days
Primary Outcome Measure Information:
Title
Duration of Erythema migrans (EM)
Description
On day 1 duration until first the consulation is registered. Day 1-14 the EM is registered in a patient diary. On day 14 the doctor is asked whether the EM has disseapeared. If not the patient is followed by phone from the researchers. On day 90 they are additionally asked for how long it lasted.
Time Frame
1-90 days
Secondary Outcome Measure Information:
Title
Subjective Health Complaints (SHC)
Description
By questionnaire on day 1, day 90 and day 360 the patients are asked about their SHC which is a standardized set of parametres. The 3 treatment groups are compaired to each other and to 1200 healthy blood donors receiving the same questionnaire. There are 29 standardized and 3 Lyme disease related subjects to be measured.
Time Frame
1 year
Title
Borrelia antibodies
Description
Normally antibody production is not measured for EM as it is a clinical diagnosis, and less than 50 percent of EM-patients are expected to develop antibodies in the first period. However antibodies are here measured on day 1, day 14 and day 90 to see whether there are differences between the groups. Also the results will be compared to the blood donors.
Time Frame
1-90 days
Title
Side symptoms
Description
The EM in it self is often asymptomatic, and fever, headache and nerval palsy can be a sign of disseminated disease or co-infection. On the quiestionnaire to the pasient and doctor on day 1, in the patient diary day 1-14 and on the questionnaire to the doctor on day 14 these side symptoms are registered. In a potential case, where it turns out that the patient suffers from disseminated disease this will be regostered as treatment failure in the study and the patient treated and/or referred as normal.
Time Frame
1-14 days
Title
Side effects
Description
The antibiotic tretments are expected to be non-inferior to each other. Potensial side effects as nausea, diarrhea etc. are registered in the patients diary day 1-14 and in the doctors quiestionnaire on day 14.
Time Frame
1-14 days
Title
Subgrouping and TBE
Description
For volunteers there is an additional PCR-analysis on punch biopsy from the EM for subgroupring of the Borrelia bacteria. TBE-antibodies are measured on day 14.
Time Frame
1-14 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of Erythema migrans Over the age of 18 Signing an concent form after information in writing Exclusion Criteria: Allergic to any of the three drugs in the study Under the age of 18 Pregnancy Dementia or known drug abuse Antibiotic treatment last 14 days Concommitant Chemotherapy or immunomodulating therapy Concommitant use of medicine with potential interaction (defined in protocol)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Morten Lindbak, Professor
Organizational Affiliation
University of Oslo
Official's Role
Principal Investigator
Facility Information:
Facility Name
Antibiotic Centre for Primary Care, University of Oslo
City
Oslo
ZIP/Postal Code
0318
Country
Norway

12. IPD Sharing Statement

Citations:
PubMed Identifier
29505880
Citation
Eliassen KE, Reiso H, Berild D, Lindbaek M. Comparison of phenoxymethylpenicillin, amoxicillin, and doxycycline for erythema migrans in general practice. A randomized controlled trial with a 1-year follow-up. Clin Microbiol Infect. 2018 Dec;24(12):1290-1296. doi: 10.1016/j.cmi.2018.02.028. Epub 2018 Mar 2.
Results Reference
derived
Links:
URL
http://www.antibiotikasenteret.no
Description
Information from the Antibiotic Centre for Primary Care

Learn more about this trial

Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice

We'll reach out to this number within 24 hrs